Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics' Capital Leases history runs 3 years deep, the most recent figure standing at $122000.0 for Q3 2025.

• On a quarterly basis, Capital Leases fell 20.26% year-over-year to $122000.0 in Q3 2025; TTM through Sep 2025 was $122000.0, a 20.26% decrease from a year earlier, with the FY2024 full-year figure at $146000.0, down 15.61% from the prior year.
• Capital Leases eased to $122000.0 in Q3 2025 per AQST's latest filing, from $130000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $173000.0 in Q4 2023 and bottomed at $122000.0 in Q3 2025.
• The 3-year median for Capital Leases is $149500.0 (2024), against an average of $148625.0.
• Across the five-year window, Capital Leases slipped 15.61% in 2024 and slipped 20.26% in 2025, its largest moves.
• Year by year, Capital Leases stood at $173000.0 in 2023, then slipped by 15.61% to $146000.0 in 2024, then dropped by 16.44% to $122000.0 in 2025.
• Per Business Quant, the three latest AQST Capital Leases figures stand at $122000.0 (Q3 2025), $130000.0 (Q2 2025), and $138000.0 (Q1 2025).